GlassScriptPhysician profile
Angela M Meyer
NPI 1669413563
$11,724.57
in general payments reported to CMS, 2019-2025
52 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,481 · 2020: $1,115 · 2021: $1,479 · 2022: $1,617 · 2023: $2,525 · 2024: $1,744 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,031.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,623.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,095.71 | 2019-2024 | Repatha, Otezla, Evenity |
| Abbvie INC. | $976.73 | 2020-2025 | |
| Pfizer INC. | $910.59 | 2019-2025 | |
| Novo Nordisk INC | $795.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $766.20 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $476.72 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $465.68 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $436.52 | 2019-2023 | Xarelto, Spravato |
| Astellas Pharma US INC | $368.78 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $264.65 | 2019-2023 | Verquvo, Belsomra |
| Biohaven Pharmaceuticals, INC. | $259.73 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $247.37 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $183.13 | 2019-2024 | |
| Dexcom, INC. | $166.17 | 2022-2025 | Dexcom G6 Transmitter |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.